# A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection

> **NCT02498015** · PHASE4 · COMPLETED · sponsor: **Kirby Institute** · enrollment: 87 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** "3D" regimen
- **DRUG:** "3D" regimen with ribavirin

## Key facts

- **NCT ID:** NCT02498015
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-08
- **Final completion:** 2019-03
- **Target enrollment:** 87 (ACTUAL)
- **Last updated:** 2019-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02498015

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02498015, "A Phase IV Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir for Chronic Hepatitis C Genotype 1 Virus Infection". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02498015. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*